GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Cyclically Adjusted Book per Share

Heidelberg Pharma AG (XTER:HPHA) Cyclically Adjusted Book per Share : €0.89 (As of Feb. 2025)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Heidelberg Pharma AG's adjusted book value per share for the three months ended in Feb. 2025 was €0.538. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.89 for the trailing ten years ended in Feb. 2025.

During the past 12 months, Heidelberg Pharma AG's average Cyclically Adjusted Book Growth Rate was -9.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -7.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -1.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Heidelberg Pharma AG was 3.80% per year. The lowest was -7.00% per year. And the median was 2.00% per year.

As of today (2025-05-30), Heidelberg Pharma AG's current stock price is €3.38. Heidelberg Pharma AG's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2025 was €0.89. Heidelberg Pharma AG's Cyclically Adjusted PB Ratio of today is 3.80.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Heidelberg Pharma AG was 8.80. The lowest was 1.64. And the median was 3.35.


Heidelberg Pharma AG Cyclically Adjusted Book per Share Historical Data

The historical data trend for Heidelberg Pharma AG's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Cyclically Adjusted Book per Share Chart

Heidelberg Pharma AG Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.97 1.13 1.09 0.99 0.91

Heidelberg Pharma AG Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.97 0.94 0.91 0.89

Competitive Comparison of Heidelberg Pharma AG's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Heidelberg Pharma AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Cyclically Adjusted PB Ratio falls into.


;
;

Heidelberg Pharma AG Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Heidelberg Pharma AG's adjusted Book Value per Share data for the three months ended in Feb. 2025 was:

Adj_Book= Book Value per Share /CPI of Feb. 2025 (Change)*Current CPI (Feb. 2025)
=0.538/127.3575*127.3575
=0.538

Current CPI (Feb. 2025) = 127.3575.

Heidelberg Pharma AG Quarterly Data

Book Value per Share CPI Adj_Book
201505 1.451 100.417 1.840
201508 1.283 100.617 1.624
201511 0.974 99.717 1.244
201602 0.974 99.317 1.249
201605 1.016 100.617 1.286
201608 0.890 101.017 1.122
201611 0.724 100.517 0.917
201702 0.581 101.217 0.731
201705 0.676 101.817 0.846
201708 0.463 102.617 0.575
201711 1.649 102.117 2.057
201802 1.233 102.317 1.535
201805 1.157 103.917 1.418
201808 1.067 104.517 1.300
201811 0.920 104.217 1.124
201902 0.814 103.817 0.999
201905 0.766 105.418 0.925
201908 0.731 106.018 0.878
201911 0.578 105.318 0.699
202002 0.422 105.618 0.509
202005 0.694 106.018 0.834
202008 0.599 106.018 0.720
202011 0.415 105.018 0.503
202102 0.213 107.018 0.253
202105 -0.002 108.170 -0.002
202108 0.402 109.118 0.469
202111 0.196 110.173 0.227
202202 -0.011 111.754 -0.013
202205 -0.046 115.760 -0.051
202208 -0.178 116.709 -0.194
202211 1.431 119.872 1.520
202302 1.292 121.454 1.355
202305 1.092 122.824 1.132
202308 1.105 123.878 1.136
202311 1.059 123.668 1.091
202402 0.968 124.511 0.990
202405 0.883 125.776 0.894
202408 0.769 126.198 0.776
202411 0.662 126.409 0.667
202502 0.538 127.358 0.538

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Heidelberg Pharma AG  (XTER:HPHA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Heidelberg Pharma AG's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.38/0.89
=3.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Heidelberg Pharma AG was 8.80. The lowest was 1.64. And the median was 3.35.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Heidelberg Pharma AG Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG Business Description

Industry
Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Walter Miller Board of Directors
Dr. Georg F. Baur Supervisory Board
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG Headlines

No Headlines